Riemerella anatipestifer Infection in Ducks: Septicemia and Serositis

Etiology and Taxonomic Classification

Riemerella anatipestifer is a nonmotile, Gram-negative, rod-shaped bacterium belonging to the family Weeksellaceae within the phylum Bacteroidetes. The organism was historically classified as Moraxella anatipestifer and later as Pasteurella anatipestifer before being reclassified into the genus Riemerella based on 16S rRNA sequencing and DNA-DNA hybridization data. The bacterium produces small, transparent, convex colonies on blood agar or tryptic soy agar and does not ferment carbohydrates. It is catalase-positive, oxidase-positive, and does not produce indole. At least 21 serotypes have been described based on heat-stable somatic antigens, with serotypes 1, 2, and 3 being most frequently isolated in commercial duck operations. The organism is strictly host-adapted to waterfowl and turkeys and does not cause disease in mammals, a feature that distinguishes it from zoonotic avian bacterial pathogens such as those described in Livestock Zoonoses: A Comprehensive Overview of Bacterial and Viral Diseases.

Epidemiology and Host Range

Riemerella anatipestifer is a global pathogen of domestic ducks, particularly Pekin ducks (Anas platyrhynchos domestica), and is also pathogenic in Muscovy ducks, geese, and turkeys. Chickens and other galliform species are considered resistant to clinical disease. The bacterium is transmitted horizontally via the respiratory route and through contaminated water, feed, and fomites. Vertical transmission has not been conclusively demonstrated. Outbreaks typically occur in ducklings between 2 and 8 weeks of age, with morbidity reaching 70% and mortality ranging from 5% to 75% depending on serotype virulence, flock immunity, and environmental stress factors. A large-scale epidemiological investigation conducted in Shandong Province, China, from March 2020 to March 2022 examined 586 isolates from commercial duck farms and reported that serotypes 1, 2, 6, and 10 predominated, with multidrug resistance observed in over 60% of isolates [1]. That study underscored the expanding geographic distribution and evolving antimicrobial resistance profiles of R. anatipestifer in intensively farmed duck populations.

Pathogenesis and Virulence Mechanisms

The pathogenesis of R. anatipestifer involves invasion of the respiratory epithelium, followed by bacteremic dissemination to serosal surfaces, joints, and the central nervous system. The bacterium expresses several virulence factors, including outer membrane proteins (OMPs), lipopolysaccharide (LPS), and extracellular enzymes such as metalloproteases. Outer membrane vesicles (OMVs) released by R. anatipestifer strain SX-1 have been characterized by proteomic analysis, revealing the presence of 142 proteins, including known virulence-associated factors such as OmpA, OmpW, and TonB-dependent receptors [2]. These OMVs are believed to facilitate intercellular communication, host cell modulation, and immune evasion.

The PhoP/PhoQ two-component regulatory system plays a central role in virulence regulation in R. anatipestifer. A genome-wide analysis demonstrated that PhoP regulates the transcription of multiple genes involved in LPS modification, cation transport, and stress resistance [3]. PhoP-deficient mutants showed significantly reduced survival in duck serum and attenuated virulence in a duckling infection model, confirming that this regulatory system is essential for full pathogenicity. The ability of R. anatipestifer to survive within duck macrophages and resist complement-mediated killing is a hallmark of its invasive capacity. The bacterium's resistance to cationic antimicrobial peptides is mediated in part by the PhoP-regulated modification of lipid A, reducing the net negative charge of the outer membrane.

Clinical Signs and Gross Pathology

Riemerella anatipestifer duck septicemia serositis presents as an acute to subacute disease characterized by fibrinous inflammation of serous membranes and systemic bacterial dissemination. Clinical signs in affected ducklings include depression, anorexia, ocular and nasal discharge, diarrhea, ataxia, tremors, opisthotonos, and recumbency. The incubation period ranges from 2 to 5 days after natural exposure. In peracute cases, death may occur without premonitory signs.

Postmortem examination typically reveals the following lesions:

• Fibrinous pericarditis: the pericardial sac is distended with yellow, fibrinous exudate, and the epicardial surface is coated with a shaggy layer of fibrin.
• Fibrinous perihepatitis: the liver capsule is covered by a thin to thick layer of fibrin, often causing adhesion to the diaphragm or body wall.
• Fibrinous airsacculitis: the thoracic and abdominal air sacs are opaque, thickened, and contain fibrinous strands or plaques.
• Fibrinous peritonitis: serosanguinous to fibrinous fluid is present in the peritoneal cavity.
• Splenomegaly: the spleen is enlarged, mottled, and may contain necrotic foci.
• Meningoencephalitis: fibrinopurulent exudate is observed on the meningeal surfaces, particularly over the cerebral hemispheres and cerebellum.
• Arthritis and tenosynovitis: joint spaces, particularly the hock and stifle, contain viscous, purulent to fibrinous exudate.

Histopathologic examination reveals multifocal necrosis in the liver and spleen, fibrinous exudate on serosal surfaces, infiltration of heterophils and macrophages, and vasculitis with thrombosis in affected organs. The fibrinocellular exudate in the meninges and joint capsules is characteristic of the serositis component of the disease.

The differential diagnosis should include Avian Cholera in Waterfowl: Pasteurella multocida Serotypes, Outbreak Dynamics, and Vaccination, Fowl Cholera in Poultry: Pasteurella multocida Pathogenesis, Clinical Signs, Prevention, Control, and WOAH Classification, Escherichia coli in Chickens and Poultry Products, Infectious Coryza in Poultry and Ducks, and Ornithobacterium rhinotracheale (ORT). Coinfections with duck hepatitis virus, duck Tembusu virus, and Riemerella anatipestifer are common in commercial duck flocks and complicate clinical diagnosis.

Diagnostic Approaches

Definitive diagnosis of Riemerella anatipestifer duck septicemia serositis requires laboratory confirmation. The following diagnostic modalities are used:

Bacteriological Culture and Isolation

Samples from heart blood, liver, spleen, brain, and fibrinous exudate are streaked onto blood agar or tryptic soy agar and incubated microaerophilically at 37 degrees Celsius for 24 to 48 hours. R. anatipestifer produces small (0.5 to 1.0 mm), smooth, transparent, nonhemolytic colonies. The organism is catalase-positive, oxidase-positive, and urease-negative. Biochemical identification can be performed using commercial identification systems, though misidentification as Pasteurella multocida or Moraxella species is possible without specific antisera.

Molecular Detection

Polymerase chain reaction (PCR) assays targeting the 16S rRNA gene or the outer membrane protein A (ompA) gene provide rapid and specific detection. Real-time PCR and multiplex PCR panels that differentiate R. anatipestifer from other avian bacterial pathogens are available in reference laboratories.

Immunochromatographic Assays

Colloidal gold immunochromatographic strips for the detection of R. anatipestifer have been developed. These strips, which use monoclonal antibodies against conserved OMP antigens, provide a rapid, equipment-free diagnostic tool suitable for field deployment [4]. Reported sensitivity and specificity exceed 90% for experimentally infected ducks, making these strips useful for preliminary screening in outbreak settings.

Proteomic Analysis

Proteomic analysis of bacterial isolates using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) can rapidly identify R. anatipestifer at the species level. The proteomic characterization of OMVs [2] has also identified potential biomarker candidates for diagnostic assay development and vaccine antigen selection.

The following Mermaid diagram illustrates a recommended diagnostic workflow for suspected R. anatipestifer infection:

flowchart TD
    A["Duckling with neurologic signs, sudden death, or serositis"], > B{"Postmortem examination"}
    B, > C["Fibrinous pericarditis, perihepatitis, airsacculitis"]
    B, > D["No characteristic serositis lesions"]
    C, > E["Collect heart blood, liver, spleen, brain, fibrinous exudate"]
    D, > F["Consider other pathogens: Pasteurella multocida, E. coli, viral hepatitis"]
    E, > G{"Bacterial culture on blood agar or TSA"}
    G, > H["Small transparent colonies after 24-48 h"]
    H, > I{"Confirmatory testing"}
    I, > J["PCR (16S rRNA or ompA)"]
    I, > K["Colloidal gold immunochromatographic strip"]
    I, > L["MALDI-TOF MS"]
    I, > M["Biochemical panel (catalase+, oxidase+, urease-)"]
    J, > N["Confirmed R. anatipestifer"]
    K, > N
    L, > N
    M, > N
    N, > O["Antimicrobial susceptibility testing (disk diffusion or broth microdilution)"]
    O, > P["Select targeted therapy; implement biosecurity measures"]

Antimicrobial Therapy and Resistance

Antimicrobial treatment is the primary intervention for reducing mortality in acute outbreaks. However, widespread and often empirical use of antibiotics in duck production has driven the emergence of multidrug-resistant strains. The Shandong Province surveillance study documented resistance rates exceeding 80% for tetracyclines, sulfonamides, and certain aminoglycosides, with moderate susceptibility remaining for florfenicol, ceftiofur, and enrofloxacin [1].

Florfenicol Pharmacokinetics and Pharmacodynamics

Florfenicol, a fluorinated analog of thiamphenicol, is a commonly used therapeutic agent against R. anatipestifer. A comprehensive in vivo pharmacokinetic and pharmacodynamic (PK/PD) study in ducks established the optimal dosing regimen for florfenicol against R. anatipestifer [5]. The study determined that a dose of 20 mg per kg body weight administered orally every 12 hours maintained plasma concentrations above the minimum inhibitory concentration (MIC) for the entire dosing interval. The PK/PD cutoff value derived from that study supports the use of florfenicol as a first-line agent in regions where susceptibility is retained. The mechanism of action involves binding to the 50S ribosomal subunit and inhibiting peptidyltransferase activity, thereby blocking protein synthesis.

Efflux Pump Inhibition and Neomycin Sensitivity

Efflux pump overexpression is a major mechanism of acquired resistance in R. anatipestifer. The efflux pump inhibitor phenylalanine-arginine beta-naphthylamide (PAβN) has been shown to enhance neomycin sensitivity both in vitro and in vivo [6]. In that study, PAβN reduced the MIC of neomycin by 4- to 16-fold in resistant isolates and improved survival in experimentally infected ducklings when coadministered with neomycin. This finding suggests that efflux pump inhibitors could be used as adjunctive therapy to restore the efficacy of aminoglycosides, though no commercial formulation is currently available for veterinary use.

Antimicrobial Susceptibility Testing

The Clinical and Laboratory Standards Institute (CLSI) has not established specific interpretive breakpoints for R. anatipestifer. Most laboratories use broth microdilution or disk diffusion methods with breakpoints extrapolated from other veterinary bacterial pathogens. Minimum inhibitory concentration distributions for florfenicol, enrofloxacin, ceftiofur, doxycycline, and neomycin should be determined on a farm-by-farm basis given the geographic and temporal variability in resistance profiles [1]. Molecular detection of resistance genes, including those encoding aminoglycoside-modifying enzymes, tetracycline efflux pumps, and beta-lactamases, can supplement phenotypic testing.

Vaccination and Immunoprophylaxis

Vaccination is a critical component of long-term control strategies for R. anatipestifer duck septicemia serositis. Both inactivated bacterins and live attenuated vaccines have been developed, but serotype-specific immunity limits the breadth of protection, and at least 21 serotypes complicate vaccine design.

Recombinant Subunit Vaccines

A recombinant vaccine based on the outer membrane protein A (OmpA) of R. anatipestifer fused with duck IgY Fc fragment and adjuvanted with Schisandra chinensis polysaccharide has been evaluated in ducklings [7]. That study demonstrated that the fusion protein elicited significantly higher antibody titers and conferred 80% protection against homologous challenge compared with 40% protection in the OmpA-only group. The polysaccharide adjuvant enhanced dendritic cell activation and promoted a balanced Th1/Th2 response. This approach illustrates the potential for Fc-fusion technology to improve immunogenicity in avian species.

Egg Yolk Immunoglobulin (IgY) Passive Immunization

Passive immunization using specific egg yolk immunoglobulin Y (IgY) raised against R. anatipestifer has shown prophylactic and therapeutic efficacy. Ducklings orally administered anti-R. anatipestifer IgY at 1 day of age and then challenged with a virulent strain exhibited significantly reduced mortality and bacterial load in target organs [8]. IgY antibodies are stable in the gastrointestinal tract and can be produced cost-effectively from immunized hens, making this approach suitable for field application in areas where vaccine infrastructure is limited.

Genetic Tools for Vaccine Development

The construction of shuttle plasmids capable of replicating in both Escherichia coli and R. anatipestifer has facilitated genetic manipulation of the bacterium for rational vaccine design. The shuttle plasmid pFY02, which carries the pMMB67EH origin and a chloramphenicol resistance marker, allows for the expression of heterologous antigens and the creation of defined gene deletion mutants [9]. This tool has been used to generate attenuated strains by deleting virulence-associated genes such as phoP and ompA, providing candidate live vaccines that may confer broader cross-serotype protection.

Control and Biosecurity Measures

Effective control of R. anatipestifer in commercial duck flocks requires an integrated approach combining vaccination, antimicrobial stewardship, biosecurity, and environmental management. Key measures include:

• All-in/all-out production systems to break the cycle of environmental contamination.
• Thorough cleaning and disinfection of houses, equipment, and water lines between flocks. Organic material must be removed before applying disinfectants such as quaternary ammonium compounds or chlorhexidine, which are effective against R. anatipestifer in the absence of organic load.
• Chlorination or acidification of drinking water to reduce bacterial load.
• Reduction of stocking density to limit respiratory transmission among ducklings.
• Separation of age groups and isolation of affected flocks.
• Routine surveillance using culture or PCR to detect subclinical carriage, particularly in replacement breeding stock.
• Antimicrobial susceptibility monitoring at the farm level to guide rational therapy and detect emerging resistance.

R. anatipestifer can survive for extended periods in moist organic matter and water, and contaminated fomites such as boots, clothing, and transport vehicles are important vectors for inter-farm spread. Biosecurity protocols should include dedicated footwear and equipment for each house, footbaths with effective disinfectants, and restricted access for personnel and visitors.

The economic impact of R. anatipestifer duck septicemia serositis is substantial, with losses attributable to mortality, reduced growth performance, carcass condemnation at slaughter, and the cost of antimicrobials and vaccines. In regions with intensive duck production, such as Southeast Asia and parts of Europe, the disease is considered one of the most important bacterial threats to the industry. The emergence of multidrug-resistant strains, as documented in the Shandong Province investigation [1], underscores the urgency of developing effective vaccines and implementing antimicrobial stewardship programs.

References

[1] Lyu Z, Han S, Li J, et al. Epidemiological investigation and drug resistance characteristics of Riemerella anatipestifer strains from large-scale duck farms in Shandong Province, China from March 2020 to March 2022. Poult Sci. 2023. https://pubmed.ncbi.nlm.nih.gov/37209657/

[2] Wang Y, Deng J, Wang X, et al. Isolation, identification, and proteomic analysis of outer membrane vesicles of Riemerella anatipestifer SX-1. Poult Sci. 2024. https://pubmed.ncbi.nlm.nih.gov/38547673/

[3] Zhang Y, Wang Y, Zhang Y, et al. Genome-Wide Analysis Reveals that PhoP Regulates Pathogenicity in Riemerella anatipestifer. Microbiol Spectr. 2022. https://pubmed.ncbi.nlm.nih.gov/36197298/

[4] Hou W, Wang S, Wang X, et al. Development of colloidal gold immunochromatographic strips for detection of Riemerella anatipestifer. PLoS One. 2015. https://pubmed.ncbi.nlm.nih.gov/25822983/

[5] Zhang HL, Li FL, Chen HY, et al. In vivo pharmacokinetic and pharmacodynamic study and cutoff of florfenicol against Riemerella anatipestifer in ducks. Poult Sci. 2025. https://pubmed.ncbi.nlm.nih.gov/39647361/

[6] Liu S, Liu J, Fu N, et al. Phenylalanine-arginine beta-naphthylamide could enhance neomycin-sensitivity on Riemerella anatipestifer in vitro and in vivo. Front Microbiol. 2022. https://pubmed.ncbi.nlm.nih.gov/36713163/

[7] Yang S, Dong W, Li G, et al. A recombinant vaccine of Riemerella anatipestifer OmpA fused with duck IgY Fc and Schisandra chinensis polysaccharide adjuvant enhance protective immune response. Microb Pathog. 2019. https://pubmed.ncbi.nlm.nih.gov/31491549/

[8] Yang D, Mai K, Zhou Q, et al. The protective efficacy of specific egg yolk immunoglobulin Y(IgY) against Riemerella Anatipestifer infections. Vet Microbiol. 2020. https://pubmed.ncbi.nlm.nih.gov/32273021/

[9] Feng Y, Cheng A, Liu M. Construction and application of Escherichia Coli-Riemerella anatipestifer efficient shuttle plasmid pFY02. Sheng Wu Gong Cheng Xue Bao. 2018. https://pubmed.ncbi.nlm.nih.gov/30394027/